Galecto reports GB2064 reduces bone marrow fibrosis in 4 of 5 evaluable myelofibrosis patients

Damora Therapeutics, Inc.

Four of five evaluable patients on GB2064 achieved ≥1-grade reduction in collagen fibrosis over 6 months.
All four fibrosis responders showed stable hemoglobin, WBC, platelets, and spleen volume; no transfusions needed.
Two patients entered extension phase due to clinical benefit as assessed by treating physician.
No treatment-related SAEs in the 5-patient evaluable group; one possible SAE (fall) in entire 16-patient trial.
Company expects top-line results from GULLIVER-2 liver cirrhosis trial in coming weeks.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.